Completed PHASE2/PHASE3 INTERVENTIONAL NCT00368173

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

Sponsor: Insmed Incorporated

Conditions Growth Hormone Insensitivity Syndrome (GHIS) Laron Syndrome

Updated 6 times since 2017 Last updated: Sep 11, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Growth Hormone Insensitivity Syndrome (GHIS) and Laron Syndrome, this trial is completed. The trial is conducted by Insmed Incorporated and has accumulated 6 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Insmed Incorporated

Data source: Insmed Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Berlin, Germany , Buenos Aires, Argentina , Cairo, Egypt , Haifa, Israel , Hong Kong, China , Košice, Slovakia , Lima, Peru , London, United Kingdom , Naples, Italy and 5 more locations